Hotline 24/7: 0909384389

Share links:

Women underrepresented in cardiovascular clinical trial leadership positions

Ngày 03/03/2022 02:54 | Lượt xem: 876

Women remain underrepresented in leading cardiovascular clinical trials, corresponding with underrepresentation and a lack of gender diversity among presenters at scientific meetings, according to a review published in the Journal of the American College of Cardiology (JACC).

A previous analysis of cardiovascular trials published over the last four years found that women comprised only 10.1% of clinical trial leadership committees, and more than half of the trials had no women as part of the trial leadership team. Other research has also found a correlation between women leading clinical trials and the number of women participating in clinical trials. Historically, clinical trials have largely enrolled white men, and participation has been low among women, older adults and racial/ethnic minorities.

The current review highlights gender diversity of panellists and session chairs at the recent American College of Cardiology (ACC) Scientific Sessions, but demonstrates that 93% of the clinical trial results were presented by men.

“These problems are, unfortunately, cyclical in nature. A lack of women in leadership positions on clinical trials results in fewer women participating in the trials. The fewer women participating in studies means that medications and other therapies are not ensured to be safe and effective for everyone,” said Mary Norine Walsh (Ascension St Vincent Heart Center, Indianapolis, USA), author of the paper. “Fewer women leading clinical trials also means fewer women presenting pivotal, practice-changing trial results at scientific meetings.’

Walsh said that increasing the number of women on trial steering committees needs to start at a deeper level. Mentorship in early career is crucial as is knowledge of clinical trial committee structure. To help ensure this, medical societies have begun to release recommendations and roadmaps to foster change, including the ACC’s “Clinical Trial Research: Upping Your Game” programme, designed to help develop and train the next generation of women and underrepresented minorities as clinical trialists.

“We are starting to see work being done to close the gap in representation, but more needs to be done,” Walsh said. “Scientific sessions and meeting planners only have so much influence over who is presenting at conferences. This comes down to senior clinical trialists relinquishing the podium and giving a leg up to others.”

Walsh laid out steps to increase representation in clinical trial leadership, including that sponsors of clinical trials need to insist on diversity of the trial steering committee; investigators asked to lead clinical trials must consider geographic, institutional and trial site diversity, along with a diverse slate of experienced investigators in leadership positions; institutions, department chairs and division chiefs need to encourage women to serve as site principal investigators; the informal, or formal, pecking order of cardiovascular trial leadership needs to be reworked, and; women should not be tapped for clinical trial leadership, and late-breaking results reporting, solely if the trial is pertinent only to a female patient population.

“There will be no room at the top for new and innovative investigators to shine if those who have already achieved success do not make room,” Walsh said.

A panel session at the European Society of Cardio-Thoracic Surgery annual meeting (EACTS 2021; 13–16 October; Barcelona, Spain and virtual) considered current data concerning women undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI), with speakers concluding that the underrepresentation of women in clinical coronary revascularisation trials on a patient level may encourage treatment that favours outcomes in men, despite the presence of significant differences in the clinical characteristics between women and men.

Source CardiovascularNews

Duc Tin CLinic

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support